Q-Line Biotech (NSE:QLINE) LT-Debt-to-Total-Asset: 0.18 (As of Mar. 2025)


NSE:QLINE Q-Line Biotech Ltd NSE:QLINE
12 GF Score
Price ₹546.50
! 2 Warning Signs
View Full Analysis

What is Q-Line Biotech LT-Debt-to-Total-Asset?

Q-Line Biotech NSE:QLINE -5.15% 12 LT-Debt-to-Total-Asset is 0.18 as of Mar. 2025. GuruFocus rates NSE:QLINE with a GF Score™ of 12/100. The stock has 2 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Q-Line Biotech's long-term debt to total assests ratio for the quarter that ended in Mar. 2025 was 0.18.

Q-Line Biotech's long-term debt to total assets ratio increased from Mar. 2023 (0.06) to Mar. 2025 (0.18). It may suggest that Q-Line Biotech is progressively becoming more dependent on debt to grow their business.

Q-Line Biotech  (NSE:QLINE) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Q-Line Biotech LT-Debt-to-Total-Asset Related Terms

Q-Line Biotech LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Q-Line Biotech's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Q-Line Biotech LT-Debt-to-Total-Asset Chart

Q-Line Biotech Annual Data
Trend Mar23 Mar24 Mar25
LT-Debt-to-Total-Asset
0.06 0.10 0.18

Q-Line Biotech Semi-Annual Data
Mar23 Mar24 Mar25
LT-Debt-to-Total-Asset 0.06 0.10 0.18
NSE:QLINE
12GF Score
Q-Line Biotech Ltd NSE:QLINE
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Q-Line Biotech LT-Debt-to-Total-Asset Calculation

Q-Line Biotech's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Mar. 2025 is calculated as

LT Debt to Total Assets (A: Mar. 2025 )=Long-Term Debt & Capital Lease Obligation (A: Mar. 2025 )/Total Assets (A: Mar. 2025 )
=824.118/4554.859
=0.18

Q-Line Biotech's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2025 is calculated as

LT Debt to Total Assets (Q: Mar. 2025 )=Long-Term Debt & Capital Lease Obligation (Q: Mar. 2025 )/Total Assets (Q: Mar. 2025 )
=824.118/4554.859
=0.18

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.18 mean?
Q-Line Biotech (NSE:QLINE) has a LT-Debt-to-Total-Asset of 0.18 as of Mar. 2025. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Q-Line Biotech and its competitors.
Is Q-Line Biotech's LT-Debt-to-Total-Asset too high?
Q-Line Biotech's current LT-Debt-to-Total-Asset is 0.18. Overall, Q-Line Biotech has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Q-Line Biotech's LT-Debt-to-Total-Asset compare to ABT and SYK?
Q-Line Biotech's LT-Debt-to-Total-Asset of 0.18 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Medical Devices & Instruments company?
A good LT-Debt-to-Total-Asset depends on the Medical Devices & Instruments industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Q-Line Biotech and its competitors. Q-Line Biotech's current LT-Debt-to-Total-Asset is 0.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Q-Line Biotech stock overvalued right now?
Q-Line Biotech (NSE:QLINE) has a current LT-Debt-to-Total-Asset of 0.18. The current LT-Debt-to-Total-Asset is 0.18. Q-Line Biotech's overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Q-Line Biotech (NSE:QLINE), the current LT-Debt-to-Total-Asset is 0.18 as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Q-Line Biotech Business Description

Address Kanpur Road Adjacent Transport Nagar Metro Station, 298-281, Transport Nagar, Lucknow, UP, IND, 226012
Q-Line Biotech Ltd is engaged in the business of developing, manufacturing and marketing of diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs. The company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs directly or through its distributors majorly to diagnostic service providers, hospitals and medical colleges. It is engaged in Manufacturing and Trading into Biochemistry Regnant, Instruments and Consumables. The majority of revenue is derived from the Manufacturing segment.
12GF Score

Get the complete analysis for NSE:QLINE

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹546.50
Price